Alvotech ( NASDAQ:ALVO ) just reported some strong earnings, and the market reacted accordingly with a healthy ...

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to ...

Selardsdi is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding ...

It announces that Alvogen Lux Holdings S.ár.l., the second largest shareholder in Alvotech, has acquired 210,000 shares at ISK 1,277.38 each. The largest shareholders in Alvogen Lux Holdings are ...

Learn more about whether Alvotech or BioCryst Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Good day, and thank you for standing by. Welcome to the Alvotech Q1 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation ...

Alvotech anticipates that potential U.S. tariffs on imported pharmaceuticals will have minimal impact on their product revenues, estimated at less than 1% for 2025. Customers will bear the costs ...

Operating profit / (loss): Operating profit was $10.6 million for the three months ended 31 March 2025, compared to ($48.4) ...

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple ...